Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance

Journal of Cardiovascular Magnetic Resonance

Volumn 15, Issue 1, 2013, Pages

  Vasu, Sujethra ^a   Bandettini, W Patricia ^b   Hsu, Li Yueh ^b   Kellman, Peter ^b   Leung, Steve ^b   Mancini, Christine ^b   Shanbhag, Sujata M ^b   Wilson, Joel ^b   Booker, Oscar Julian ^c   Arai, Andrew E ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenosine; Dipyridamole; Magnetic resonance imaging; Quantitative myocardial perfusion; Regadenoson

Indexed keywords

ADENOSINE; DIPYRIDAMOLE; GADOLINIUM PENTETATE MEGLUMINE; REGADENOSON;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; FRAMINGHAM RISK SCORE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HEART RATE; HEART STRESS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESTING HEART RATE; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ADENOSINE; CORONARY CIRCULATION; DIPYRIDAMOLE; FEMALE; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; INFUSIONS, PARENTERAL; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIAL PERFUSION IMAGING; PREDICTIVE VALUE OF TESTS; PURINES; PYRAZOLES; VASODILATION; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84884637335     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-15-85     Document Type: Article

References (32)

1. Advances in pharmacologic agents in imaging: new A2A receptor agonists. Cerqueira MD, Curr Cardiol Rep 2006 8 119 22 10.1007/s11886-006-0022-1 16524538
2. Regadenoson: a new myocardial stress agent. Al Jaroudi W, Iskandrian AE, J Am Coll Cardiol 2009 54 1123 30 10.1016/j.jacc.2009.04.089 19761931
3. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, et al. J Nucl Cardiol 2007 14 645 58 10.1016/j.nuclcard.2007.06.114 17826318 (Pubitemid 47355078)
4. Advances in pharmacologic stress agents: focus on regadenoson. Johnson SG, Peters S, J Nucl Med Technol 2010 38 163 71 10.2967/jnmt.109.065581 20724531
5. Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. Zhao G, Linke A, Xu X, Ochoa M, Belloni F, Belardinelli L, Hintze TH, J Pharmacol Exp Ther 2003 307 182 9 10.1124/jpet.103.053306 12954805 (Pubitemid 37151905)
6. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. Trochu JN, Zhao G, Post H, Xu X, Belardinelli L, Belloni FL, Hintze TH, J Cardiovasc Pharmacol 2003 41 132 9 10.1097/00005344-200301000-00017 12500031 (Pubitemid 36015065)
7. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. Mekkaoui C, Jadbabaie F, Dione DP, Meoli DF, Purushothaman K, Belardinelli L, Sinusas AJ, JACC Cardiovasc Imaging 2009 2 1198 208 10.1016/j.jcmg.2009.06.013 19833310
8. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA, J Nucl Cardiol 2007 14 514 20 10.1016/j.nuclcard.2007.02.016 17679059 (Pubitemid 47163555)
9. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, Mahmarian JJ, J Am Coll Cardiol 2005 46 2069 75 10.1016/j.jacc.2005.05.097 16325044 (Pubitemid 41713594)
10. Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease. Hamon M, Fau G, Nee G, Ehtisham J, Morello R, J Cardiovasc Magn Reson 2010 12 29 10.1186/1532-429X-12-29 20482819
11. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. Klem I, Heitner JF, Shah DJ, Sketch MH Jr, Behar V, Weinsaft J, Cawley P, Parker M, Elliott M, Judd RM, Kim RJ, J Am Coll Cardiol 2006 47 1630 8 10.1016/j.jacc.2005.10.074 16631001
12. Myocardial first-pass perfusion magnetic resonance imaging: a multicenter dose-ranging study. Wolff SD, Schwitter J, Coulden R, Friedrich MG, Bluemke DA, Biederman RW, Martin ET, Lansky AJ, Kashanian F, Foo TK, et al. Circulation 2004 110 732 7 10.1161/01.CIR.0000138106.84335.62 15289374 (Pubitemid 39056274)
13. Comparison of dobutamine stress magnetic resonance, adenosine stress magnetic resonance, and adenosine stress magnetic resonance perfusion. Paetsch I, Jahnke C, Wahl A, Gebker R, Neuss M, Fleck E, Nagel E, Circulation 2004 110 835 42 10.1161/01.CIR.0000138927.00357.FB 15289384 (Pubitemid 39096012)
14. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Schwitter J, Wacker CM, van Rossum AC, Lombardi M, Al-Saadi N, Ahlstrom H, Dill T, Larsson HB, Flamm SD, Marquardt M, Johansson L, Eur Heart J 2008 29 480 9 10.1093/eurheartj/ehm617 18208849 (Pubitemid 351264187)
15. Assessment of myocardial perfusion for detection of coronary artery stenoses by steady-state, free-precession magnetic resonance first-pass imaging. Merkle N, Wohrle J, Grebe O, Nusser T, Kunze M, Kestler HA, Kochs M, Hombach V, Heart 2007 93 1381 5 10.1136/hrt.2006.104232 17488772 (Pubitemid 351480135)
16. Optimization of the arterial input function for myocardial perfusion cardiovascular magnetic resonance. Elkington AG, He T, Gatehouse PD, Prasad SK, Firmin DN, Pennell DJ, J Magn Reson Imaging 2005 21 354 9 10.1002/jmri.20294 15779035 (Pubitemid 40446428)
17. Quantitative myocardial perfusion analysis with a dual-bolus contrast-enhanced first-pass MRI technique in humans. Hsu LY, Rhoads KL, Holly JE, Kellman P, Aletras AH, Arai AE, J Magn Reson Imaging 2006 23 315 22 10.1002/jmri.20502 16463299 (Pubitemid 43364057)
18. Quantification of myocardial perfusion by cardiovascular magnetic resonance. Jerosch-Herold M, J Cardiovasc Magn Reson 2010 12 57 10.1186/1532-429X-12-57 20932314
19. Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution. Jerosch-Herold M, Wilke N, Stillman AE, Med Phys 1998 25 73 84 10.1118/1.598163 9472829 (Pubitemid 28063691)
20. Accurate assessment of the arterial input function during high-dose myocardial perfusion cardiovascular magnetic resonance. Gatehouse PD, Elkington AG, Ablitt NA, Yang GZ, Pennell DJ, Firmin DN, J Magn Reson Imaging 2004 20 39 45 10.1002/jmri.20054 15221807 (Pubitemid 38857515)
21. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L, J Pharmacol Exp Ther 2006 316 695 702 16227469 (Pubitemid 43130996)
22. Estimates of systolic and diastolic myocardial blood flow by dynamic contrast-enhanced MRI. Radjenovic A, Biglands JD, Larghat A, Ridgway JP, Ball SG, Greenwood JP, Jerosch-Herold M, Plein S, Magn Reson Med 64 1696 703
23. Using cardiac phase to order reconstruction (CAPTOR): a method to improve diastolic images. Feinstein JA, Epstein FH, Arai AE, Foo TK, Hartley MR, Balaban RS, Wolff SD, J Magn Reson Imaging 1997 7 794 8 10.1002/jmri.1880070505 9307903 (Pubitemid 28359525)
24. Comparison of exercise, dipyridamole, adenosine, and dobutamine stress with the use of Tc-99m tetrofosmin tomographic imaging. Levine MG, Ahlberg AW, Mann A, White MP, McGill CC, Mendes De Leon C, Piriz JM, Waters D, Heller GV, J Nucl Cardiol 1999 6 389 96 10.1016/S1071-3581(99)90004-1 10461605 (Pubitemid 29405960)
25. Comparison between dipyridamole and adenosine as pharmacologic coronary vasodilators in detection of coronary artery disease with thallium 201 imaging. Taillefer R, Amyot R, Turpin S, Lambert R, Pilon C, Jarry M, J Nucl Cardiol 1996 3 204 11 10.1016/S1071-3581(96)90034-3 8805740 (Pubitemid 26248479)
26. Comparison of exercise, dipyridamole, and adenosine by use of technetium 99m sestamibi tomographic imaging. Santos-Ocampo CD, Herman SD, Travin MI, Garber CE, Ahlberg AW, Messinger DE, Heller GV, J Nucl Cardiol 1994 1 57 64 10.1007/BF02940012 9420671 (Pubitemid 24257830)
27. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, Moye LA, Olmsted AW, JACC Cardiovasc Imaging 2009 2 959 68 10.1016/j.jcmg.2009.04.011 19679284
28. The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging stud y. DiBella EV, Fluckiger JU, Chen L, Kim TH, Pack NA, Matthews B, Adluru G, Priester T, Kuppahally S, Jiji R, McGann C, Litwin SE, Int J Cardiovasc Imaging. 2012 6 1435 44
29. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, Lieu HD, J Nucl Cardiol 2008 15 329 36 10.1016/j.nuclcard.2008.02.009 18513639
30. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, Mathur V, J Nucl Cardiol 2008 15 319 28 10.1016/j.nuclcard.2008.02.013 18513638
31. Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). Wang L, Jerosch-Herold M, Jacobs DR Jr, Shahar E, Folsom AR, J Am Coll Cardiol 2006 47 565 72 10.1016/j.jacc.2005.09.036 16458137 (Pubitemid 43170845)
32. Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson. Bhave NM, Freed BH, Yodwut C, Kolanczyk D, Dill K, Lang RM, Mor-Avi V, Patel AR, J Cardiovasc Magn Reson 2012 14 89 10.1186/1532-429X-14-89 23272658